Why the study?
Does the HbA1c/C-peptide ratio predict the no-reflow phenomenon in patients with ST-elevation myocardial infarction?
Does the HbA1c/C-peptide ratio predict the no-reflow phenomenon in patients with ST-elevation myocardial infarction?
Answers are grounded in this paper and cite their sources.
The HbA1c/C-peptide ratio is proposed as a potential biomarker for predicting no-reflow in STEMI patients.
In this letter, we discussed that HbA1c/C-peptide ratio is a potential biomarker used to predict no-reflow phenomenon in patients with ST-elevation myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Mo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: